Curcumin protects against collagen-induced arthritis via suppression of BAFF production

Journal of Clinical Immunology

Volumn 33, Issue 3, 2013, Pages 550-557

  Huang, Gang ^a   Xu, Zhizhen ^a   Huang, Yan ^a   Duan, Xiaojun ^a   Gong, Wei ^a   Zhang, Yan ^a   Fan, Jishan ^a   He, Fengtian ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

B lymphocyte; BAFF; Collagen induced arthritis; Curcumin; STAT1

Indexed keywords

BAFF PROTEIN; CURCUMIN; GAMMA INTERFERON; INTERLEUKIN 6; LUCIFERASE; STAT1 PROTEIN; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTHRITIS; ARTICLE; B LYMPHOCYTE; CELL NUCLEUS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE SEVERITY; DRUG EFFECT; DRUG RESPONSE; MALE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; SPLEEN CELL; TRANSCRIPTION REGULATION; WESTERN BLOTTING;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, EXPERIMENTAL; B-CELL ACTIVATING FACTOR; B-LYMPHOCYTES; CELL LINE; CELL NUCLEUS; CURCUMIN; GENE EXPRESSION REGULATION; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-6; MALE; MICE; PHOSPHORYLATION; PROTEIN TRANSPORT; STAT1 TRANSCRIPTION FACTOR;

EID: 84879886056     PISSN: 02719142     EISSN: 15732592     Source Type: Journal    
DOI: 10.1007/s10875-012-9839-0     Document Type: Article

References (40)

1. Klareskog L, Catrina AI, Paget S. Rheumatoid arthritis. Lancet. 2009;373:659-72.
2. McInnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol. 2007;7:429-42.
3. de la Torre I, Moura RA, Leandro MJ, Edwards J, Cambridge G. B-cell-activating factor receptor expression on naive and memory B cells: relationship with relapse in patients with rheumatoid arthritis following B-cell depletion therapy. Ann Rheum Dis. 2010;69:2181-8.
4. Gheita TA, Bassyouni IH, Emad Y, El-Din AM, Abdel-Rasheed E, Hussein H. Elevated BAFF (BLyS) and APRIL in Juvenile idiopathic arthritis patients: relation to clinical manifestations and disease activity. Joint Bone Spine. 2012;79:285-90.
5. Lied GA, Berstad A. Functional and clinical aspects of the B-cellactivating factor (BAFF): a narrative review. Scand J Immunol. 2010;73:1-7.
6. Mackay F, Schneider P. Cracking the BAFF code. Nat Rev Immunol. 2009;9:491-502.
7. Zhang M, Ko KH, Lam QL, Lo CK, Srivastava G, Zheng B, Lau YL, Lu L. Expression and function of TNF family member B cellactivating factor in the development of autoimmune arthritis. Int Immunol. 2005;17:1081-92.
8. Li PP, Liu DD, Liu YJ, Song SS, Wang QT, Chang Y, Wu YJ, Chen JY, Zhao WD, Zhang LL, Wei W. BAFF/BAFF-R involved in antibodies production of rats with collagen-induced arthritis via PI3K-Akt-mTOR signaling and the regulation of paeoniflorin. J Ethnopharmacol. 2012;141:290-300.
9. Gottenberg JE, Miceli-Richard C, Ducot B, Goupille P, Combe B, Mariette X. Markers of B-lymphocyte activation are elevated in patients with early rheumatoid arthritis and correlated with disease activity in the ESPOIR cohort. Arthritis Res Ther. 2009;11:R114.
10. Becker-Merok A, Nikolaisen C, Nossent HC. B-lymphocyte activating factor in systemic lupus erythematosus and rheumatoid arthritis in relation to autoantibody levels, disease measures and time. Lupus. 2006;15:570-6.
11. Pers JO, Daridon C, Devauchelle V, Jousse S, Saraux A, Jamin C, Youinou P. BAFF overexpression is associated with autoantibody production in autoimmune diseases. Ann N Y Acad Sci. 2005;1050:34-9.
12. Davidson A. Targeting BAFF in autoimmunity. Curr Opin Immunol. 2010;22:732-9.
13. Dennis GJ. Belimumab: a BLyS-specific inhibitor for the treatment of systemic lupus erythematosus. Clin Pharmacol Ther. 2012;91:143-9.
14. Liu Z, Davidson A. BAFF inhibition: a new class of drugs for the treatment of autoimmunity. Exp Cell Res. 2011;317:1270-7.
15. Recio MC, Andujar I, Rios JL. Anti-inflammatory agents from plants: progress and potential. Curr Med Chem. 2012;19:2088-103.
16. Ji JL, Huang XF, Zhu HL. Curcumin and its formulations: potential anti-cancer agents. Anticancer Agents Med Chem. 2012;12:210-8.
17. Mun SH, Kim HS, Kim JW, Ko NY, Kim do K, Lee BY, Kim B, Won HS, Shin HS, Han JW, Lee HY, Kim YM, Choi WS. Oral administration of curcumin suppresses production of matrix metalloproteinase (MMP)-1 and MMP-3 to ameliorate collagen-induced arthritis: inhibition of the PKCdelta/JNK/c-Jun pathway. J Pharmacol Sci. 2009;111:13-21.
18. Huang WT, Niu KC, Chang CK, Lin MT, Chang CP. Curcumin inhibits the increase of glutamate, hydroxyl radicals and PGE2 in the hypothalamus and reduces fever during LPS-induced systemic inflammation in rabbits. Eur J Pharmacol. 2008;593:105-11.
19. Park C, Moon DO, Choi IW, Choi BT, Nam TJ, Rhu CH, Kwon TK, Lee WH, Kim GY, Choi YH. Curcumin induces apoptosis and inhibits prostaglandin E(2) production in synovial fibroblasts of patients with rheumatoid arthritis. Int J Mol Med. 2007;20:365-72.
20. Bright JJ. Curcumin and autoimmune disease. Adv Exp Med Biol. 2007;595:425-51.
21. Jagetia GC, Aggarwal BB. "Spicing up" of the immune system by curcumin. J Clin Immunol. 2007;27:19-35.
22. Aggarwal BB, Banerjee S, Bharadwaj U, Sung B, Shishodia S, Sethi G. Curcumin induces the degradation of cyclin E expression through ubiquitin-dependent pathway and up-regulates cyclindependent kinase inhibitors p21 and p27 in multiple human tumor cell lines. Biochem Pharmacol. 2007;73:1024-32.
23. Xu Z, Huang G, Gong W, Zhou P, Zhao Y, Zhang Y, Zeng Y, Gao M, Pan Z, He F. FXR ligands protect against hepatocellular inflammation via SOCS3 induction. Cell Signal. 2012;24:1658-64.
24. Chao F, Gong W, Zheng Y, Li Y, Huang G, Gao M, Li J, Kuruba R, Gao X, Li S, He F. Upregulation of scavenger receptor class B type I expression by activation of FXR in hepatocyte. Atherosclerosis. 2010;213:443-8.
25. Ohata J, Zvaifler NJ, Nishio M, Boyle DL, Kalled SL, Carson DA, Kipps TJ. Fibroblast-like synoviocytes of mesenchymal origin express functional B cell-activating factor of the TNF family in response to proinflammatory cytokines. J Immunol. 2005;174:864-70.
26. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365:2205-19.
27. Kim HA, Jeon SH, Seo GY, Park JB, Kim PH. TGF-beta1 and IFN-gamma stimulate mouse macrophages to express BAFF via different signaling pathways. J Leukoc Biol. 2008;83:1431-9.
28. Zhou L, Zhong R, Hao W, Wang H, Fan X, Zhang L, Mi Q. Interleukin-10 and interferon-gamma up-regulate the expression of B-cell activating factor in cultured human promyelocytic leukemia cells. Exp Mol Pathol. 2009;87:54-8.
29. Rochas C, Hillion S, Saraux A, Mageed RA, Youinou P, Jamin C, Devauchelle V. Transmembrane BAFF from rheumatoid synoviocytes requires interleukin-6 to induce the expression of recombination-activating gene in B lymphocytes. Arthritis Rheum. 2009;60:1261-71.
30. Park SR, Jung MH, Jeon SH, Park MH, Park KH, Lee MR, Kim PH. IFN-gamma down-regulates TGF-beta1-induced IgA expression through Stat1 and p300 signaling. Mol Cells. 2010;29:57-62.
31. Chandran B, Goel A. A randomized, pilot study to assess the efficacy and safety of curcumin in patients with active rheumatoid arthritis. Phytother Res. 2012 in press.
32. Aggarwal BB, Harikumar KB. Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. Int J Biochem Cell Biol. 2009;41:40-59.
33. Goel A, Kunnumakkara AB, Aggarwal BB. Curcumin as "Curecumin": from kitchen to clinic. Biochem Pharmacol. 2008;75:787-809.
34. Kollias G, Papadaki P, Apparailly F, Vervoordeldonk MJ, Holmdahl R, et al. Animal models for arthritis: innovative tools for prevention and treatment. Ann Rheum Dis. 2011;70:1357-62.
35. Bevaart L, Vervoordeldonk MJ, Tak PP. Evaluation of therapeutic targets in animal models of arthritis: how does it relate to rheumatoid arthritis? Arthritis Rheum. 2010;62:2192-205.
36. Hegen M, Keith Jr JC, Collins M, Nickerson-Nutter CL. Utility of animal models for identification of potential therapeutics for rheumatoid arthritis. Ann Rheum Dis. 2008;67:1505-15.
37. Billiau A, Matthys P. Collagen-induced arthritis and related animal models: how much of their pathogenesis is auto-immune, how much is auto-inflammatory? Cytokine Growth Factor Rev. 2011;22:339-44.
38. Grimstein C, Choi YK, Wasserfall CH, Satoh M, Atkinson MA, Brantly ML, et al. Alpha-1 antitrypsin protein and gene therapies decrease autoimmunity and delay arthritis development in mouse model. J Transl Med. 2011;9:21.
39. Moon DO, Kim MO, Choi YH, Park YM, Kim GY. Curcumin attenuates inflammatory response in IL-1beta-induced human synovial fibroblasts and collagen-induced arthritis in mouse model. Int Immunopharmacol. 2010;10:605-10.
40. Scapini P, Hu Y, Chu CL, Migone TS, Defranco AL, Cassatella MA, Lowell CA. Myeloid cells, BAFF, and IFN-gamma establish an inflammatory loop that exacerbates autoimmunity in Lyn-deficient mice. J Exp Med. 2010;207:1757-73.